Bull Horn Holdings in an 8-K filing disclosed that shareholders voted in favor of merging with Coeptis Therapeutics, a biopharmaceutical company developing cell therapy platforms for cancer.
A total of 2,869,654 ordinary shares (approximately 88.5% of Bull Horn’s remaining outstanding public shares) were presented for redemption. That leaves approximately $3.8 million remaining in the trust account, Bull Horn said in the filing.
Shareholders back in April had approved a 6-month extension for Bull Horn to close the deal. Redemptions ahead of that extension vote wiped out more than half the SPAC’s cash in trust at that time.
Bull Horn in the filing said it still expects the business combination to be completed promptly following the satisfaction or waiver of the other conditions to close.
Original deal terms called for Coeptis stakeholders to receive equity in Bull Horn valued at $175 million. Read more.
